Description
ARA-290, also known by its investigational name cibinetide, is a synthetic 11-amino acid peptide derived from the tissue-protective domain of erythropoietin (EPO). Unlike native EPO, ARA-290 was deliberately engineered to strip out erythropoietic activity entirely, leaving only the tissue-protective signaling intact. This means it does not stimulate red blood cell production and carries none of the cardiovascular risks associated with elevated hematocrit.
Clinical research has evaluated ARA-290 most extensively in sarcoidosis-associated small fiber neuropathy (SFN). A randomized, placebo-controlled trial demonstrated that 4 mg subcutaneous daily injections over 28 days increased corneal nerve fiber density and significantly reduced neuropathic pain scores [3]. A parallel metabolic study found improvements in insulin sensitivity and HbA1c in patients with type 2 diabetes. The FDA granted ARA-290 Orphan Drug status for neuropathic pain in sarcoidosis.
Dosage: 4 mg once daily for 28 days
